RANK signaling blockade reduces breast cancer recurrence by inducing tumor cell differentiation

Cancer Research

Volumn 76, Issue 19, 2016, Pages 5857-5869

  Yoldi, Guillermo ^a   Pellegrini, Pasquale ^a   Trinidad, Eva M ^a   Cordero, Alex ^a   Gomez Miragaya, Jorge ^a   Serra Musach, Jordi ^a   Dougall, William C ^b   Muñoz, Purificación ^a   Pujana, Miguel Angel ^a   Planelles, Lourdes ^c   González Suárez, Eva ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b AMGEN INC   (United States)

^c CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARRIER PROTEINS AND BINDING PROTEINS; DOCETAXEL; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; R SPONDIN1; RANK FC; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STEM CELL ANTIGEN 1; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP2B; UNCLASSIFIED DRUG; VIRUS MIDDLE T ANTIGEN; WNT PROTEIN; ATAXIN 1; ATXN1 PROTEIN, HUMAN; TAXOID; TFAP2B PROTEIN, HUMAN; TNFRSF11A PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; INTRACELLULAR SIGNALING; METASTASIS INHIBITION; MILK PRODUCTION; MOUSE; MOUSE MAMMARY TUMOR VIRUS; MURINE POLYOMAVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; TRANSCRIPTION REGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; C57BL MOUSE; DRUG EFFECTS; HUMAN; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PHYSIOLOGY; PREVENTION AND CONTROL; SECONDARY; SIGNAL TRANSDUCTION; TUMOR RECURRENCE;

ANIMALS; APOPTOSIS; ATAXIN-1; CELL DIFFERENTIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, INBRED C57BL; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; TAXOIDS; TRANSCRIPTION FACTOR AP-2;

EID: 84989830946     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2745     Document Type: Article

References (47)

1. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. JNatl Cancer Inst 2008;100:672-9.
2. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021-8.
3. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003;17:1253-70.
4. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A 2010; 107:2989-94.
5. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000;103:41-50.
6. Tanos TSG, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, et al. Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med 2013;5:182ra155.
7. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010; 468:103-7.
8. Gonzalez-Suarez E. RANKL inhibition: a promising novel strategy for breast cancer treatment. Clin Transl Oncol 2011;13:222-8.
9. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, et al. Osteoclast differentiation factor RANKL controls development of progestin- driven mammary cancer. Nature 2010;468:98-102.
10. Gonzalez-Suarez E, Branstetter D, Armstrong A, Dinh H, Blumberg H, Dougall WC. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol Cell Biol 2007;27: 1442-54.
11. Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, Urruticoechea A, et al. RANK induces epithelial-mesenchymal transition and stemness in humanmammary epithelial cells and promotes tumorigenesis andmetastasis. Cancer Res 2012;72:2879-88.
12. Pellegrini P, Cordero A, Gallego MI, Dougall WC, Purificacion M, Pujana MA, et al. Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. Stem Cells 2013;31:1954-65.
13. Pfitzner BM, Branstetter D, Loibl S, Denkert C, Lederer B, Schmitt WD, et al. RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Res Treat 2014;145:307-15.
14. Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 2011;6:e19234.
15. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirusmiddle T oncogene: a transgenic mousemodel for metastatic disease. Mol Cell Biol 1992;12:954-61.
16. Maglione JE, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph SO, et al. Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 2001;61:8298-305.
17. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-24.
18. Smalley MJ. Isolation, culture and analysis of mouse mammary epithelial cells. Methods Mol Biol 2010;633:139-70.
19. Dontu G, Wicha MS. Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia 2005;10:75-86.
20. Lim E, Wu D, Pal B, Bouras T, Asselin-Labat ML, Vaillant F, et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res 2010;12: R21.
21. Anderson SM, Rudolph MC, McManaman JL, Neville MC. Key stages in mammary gland development. Secretory activation in the mammary gland: it's not just about milk protein synthesis! Breast Cancer Res 2007;9:204-18.
22. Woodfield GW, Chen Y, Bair TB, Domann FE, Weigel RJ. Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells. Genes Chromosomes Cancer 2010;49:948-62.
23. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347:70-8.
24. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003;163:2113-26.
25. Barcellos-Hoff MH, Aggeler J, Ram TG, Bissell MJ. Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development 1989; 105:223-35.
26. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007;4:359-65.
27. Span PN, Waanders E, Manders P, Heuvel JJ, Foekens JA, Watson MA, et al. Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. J Clin Oncol 2004;22:691-8.
28. Bogachek MV, Chen Y, Kulak MV, Woodfield GW, Cyr AR, Park J M, et al. Sumoylation pathway is required to maintain the basal breast cancer subtype. Cancer Cell 2014;25:748-61.
29. Cyr AR, Kulak MV, Park JM, Bogachek MV, Spanheimer PM, Woodfield GW, et al. TFAP2C governs the luminal epithelial phenotype inmammary development and carcinogenesis. Oncogene 2014;34:436-44.
30. Bar-Eli M. Role of AP-2 in tumor growth and metastasis of human melanoma. Cancer Metastasis Rev 1999;18:377-85.
31. Gee JM, Robertson JF, Ellis IO, Nicholson RI, Hurst HC. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol 1999;189:514-20.
32. Buchwalter G, Hickey MM, Cromer A, Selfors LM, Gunawardane R N, Frishman J, et al. PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells. Cancer Cell 2013;23: 753-67.
33. Cai C, Yu QC, Jiang W, Liu W, Song W, Yu H, et al. R-spondin1 is a novel hormone mediator for mammary stem cell self-renewal. Genes Dev 2014;28:2205-18.
34. Joshi PA, Waterhouse PD, Kannan N, Narala S, Fang H, Di Grappa MA, et al. RANK signaling amplifies WNT-responsive mammary progenitors through R-SPONDIN1. Stem Cell Reports 2015;5:31-44.
35. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Geneexpression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9.
36. Malanchi I, Santamaria Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2011;481:85-9.
37. Sleeman KE, Kendrick H, Robertson D, Isacke CM, Ashworth A, Smalley MJ. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol 2007;176:19-26.
38. Vaillant F, Asselin-Labat ML, Shackleton M, Forrest NC, Lindeman GJ, Visvader JE. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Res 2008;68:7711-7.
39. Cordero A, Pellegrini P, Sanz-Moreno A, Trinidad EM, Serra-Musach J, Deshpande C, et al. Rankl impairs lactogenic differentiation through inhibition of the prolactin/Stat5 pathway at midgestation. Stem Cells 2016;34:1027-39.
40. Gonzalez-Suarez E, Sanz-Moreno A. RANK as a therapeutic target in cancer. Febs J 2016;283:2018-33.
41. Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 1996;13:1701-7.
42. McPherson LA, Woodfield GW, Weigel RJ. AP2 transcription factors regulate expression of CRABPII in hormone responsive breast carcinoma. J Surg Res 2007;138:71-8.
43. McPherson LA, Loktev AV, Weigel RJ. Tumor suppressor activity of AP2alpha mediated through a direct interaction with p53. J Biol Chem 2002;277:45028-33.
44. Scibetta AG, Wong PP, Chan KV, Canosa M, Hurst HC. Dual association by TFAP2A during activation of the p21cip/CDKN1A promoter. Cell Cycle 2010;9:4525-32.
45. Jager R, Werling U, Rimpf S, Jacob A, Schorle H. Transcription factor AP- 2gamma stimulates proliferation and apoptosis and impairs differentiation in a transgenic model. Mol Cancer Res 2003;1:921-9.
46. Zhang J, Brewer S, Huang J, Williams T. Overexpression of transcription factor AP-2alpha suppresses mammary gland growth and morphogenesis. Dev Biol 2003;256:127-145.
47. Batts TD, Machado HL, Zhang Y, Creighton CJ, Li Y, Rosen JM. Stem cell antigen-1 (sca-1) regulates mammary tumor development and cell migration. PLoS One 2011;6:e27841.